- Conditions
- Asthma, Hypertension
- Interventions
- Dietary Approaches to Stop Hypertension dietary pattern
- Behavioral
- Lead sponsor
- Palo Alto Medical Foundation
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Hayward, California • San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2377–2400
of 2,796
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Amputation, Diabetes Mellitus, Peripheral Artery Disease
- Interventions
- Walking Biobehavioral Intervention, Attention Control
- Behavioral · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Cystic Fibrosis
- Interventions
- Elexacaftor-tezacaftor-ivacaftor exposure
- Drug
- Lead sponsor
- Jennifer Taylor-Cousar
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Early Breast Cancer
- Interventions
- Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 69 more
- Conditions
- Anterior Cruciate Ligament Injury
- Interventions
- Electrical Stimulation, Eccentric Exercise
- Device · Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 14 Years to 35 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Leukaemia, Lymphocytic, Chronic
- Interventions
- Ofatumumab, Bendamustine
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 6
- States / cities
- Tuscon, Arizona • Aurora, Colorado • Fort Myers, Florida + 3 more
- Conditions
- Tics, Tourette Syndrome
- Interventions
- CBIT +cTBS, CBIT +sham cTBS
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Joint Diseases
- Interventions
- Total Hip Arthroplasty Implant
- Device
- Lead sponsor
- MicroPort Orthopedics Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2033
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Englewood, Colorado
- Conditions
- Crohn Disease, Rectal Fistula
- Interventions
- EUA with seton placement if necessary, adalimumab, EUS
- Procedure · Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Anxiety Depression, Disability Physical
- Interventions
- Rauha
- Device
- Lead sponsor
- Toivoa Inc
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hepatitis C
- Interventions
- BMS-650032, BMS-790052
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Multiple Sclerosis, Adult Disease
- Interventions
- Home-based exercise, Education, Exercise plus Education
- Behavioral
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Urbana, Illinois
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Erlotinib, Docetaxel
- Drug
- Lead sponsor
- Gabi Chiorean, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 12
- States / cities
- Newark, Delaware • Chicago, Illinois • Bloomington, Indiana + 6 more
- Conditions
- Advanced Solid Cancers
- Interventions
- BMS-986301, Nivolumab, Ipilimumab
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Obesity, Weight Loss
- Interventions
- Standard Behavioral Weight Loss Treatment, AI-optimized Behavioral Weight Loss Treatment
- Behavioral
- Lead sponsor
- Oregon Research Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- soy isoflavones, neoadjuvant therapy, Placebo
- Dietary Supplement · Procedure · Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2010
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- NON-ALCOHOLIC STEATOHEPATITIS
- Interventions
- DA-1241, Sitagliptin, DA-1241 Placebo, Sitagliptin Placebo
- Drug
- Lead sponsor
- NeuroBo Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 18
- States / cities
- Coronado, California • Montclair, California • Panorama City, California + 12 more
- Conditions
- Induction of Labor Affected Fetus / Newborn
- Interventions
- amniotomy, Foley Catheter, Misoprostol
- Procedure · Device · Drug
- Lead sponsor
- Christiana Care Health Services
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Rheumatoid Arthritis
- Interventions
- tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 54
- States / cities
- Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more
- Conditions
- Hearing Loss, Partial Deafness, Hearing Disorders, Ear Diseases, Otorhinolaryngologic Diseases
- Interventions
- HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode, EAS sound processor
- Device
- Lead sponsor
- Advanced Bionics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 11
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida • Lexington, Kentucky + 7 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, sitagliptin, metformin
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 665 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Escondido, California • Fresno, California + 54 more
- Conditions
- Overweight, Obese, Spinal Cord Injury
- Interventions
- Lifestyle Intervention, Exercise Control
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Cerebrovascular Accident
- Interventions
- TR intervention, In-home messaging device., Usual care
- Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 3
- States / cities
- Decatur, Georgia • Indianapolis, Indiana • Durham, North Carolina
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Venetoclax, Gemtuzumab, Ziftomenib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas